Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(942 available)
|
|
|
immune system
|
|
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
|
|
|
• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells
|
hematopoietic system
|
|
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
|
|
|
• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells
|
cellular
|
|
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
|
mortality/aging
immune system
hematopoietic system
growth/size/body
mortality/aging
immune system
liver/biliary system
neoplasm
|
|
• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)
|
hematopoietic system
growth/size/body
mortality/aging
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
immune system
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
|
|
• impaired in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the spleen and bone marrow
• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit splenomegaly and become terminally ill unlike control mice
|
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
|
|
|
• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17
|
hematopoietic system
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
|
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
|
|
• impaired in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the spleen and bone marrow
• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17
|
cellular
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
|
growth/size/body
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
neoplasm
|
N |
• mice are protected from Lmp1-driven lymphomagenesis
|
Analysis Tools